• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Arbutus Biopharma Corp (NQ: ABUS )

    3.780 -0.100 (-2.58%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 17, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,256,348
    Open 3.800
    Bid (Size) 3.780 (20)
    Ask (Size) 3.800 (7)
    Prev. Close 3.880
    Today's Range 3.670 - 3.830
    52wk Range 1.690 - 3.890
    Shares Outstanding 99,161,234
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
    From Arbutus Biopharma Corporation
    Via GlobeNewswire

    Performance

    YTD
    +45.95%
    +45.95%
    1 Month
    +23.53%
    +23.53%
    3 Month
    +35.97%
    +35.97%
    6 Month
    +66.52%
    +66.52%
    1 Year
    +71.04%
    +71.04%

    More News

    Read More
    Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    Earnings Scheduled For February 29, 2024
    Via Benzinga
    Arbutus to Participate in Jefferies Global Healthcare Conference
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    Arbutus to Present Imdusiran Data at EASL Congress 2024
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value
    From Whitefort Capital Management, LP
    Via Business Wire
    Arbutus to Participate in Two Upcoming Investor Conferences
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    ABUS Stock Earnings: Arbutus Biopharma Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    3 Healthcare Stocks Short Sellers Are Prescribing for Trouble
    Via InvestorPlace
    Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge
    Via Benzinga
    Topics Intellectual Property
    Exposures COVID-19 Intellectual Property
    Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound Ahead
    Via Benzinga
    Topics Intellectual Property
    Exposures COVID-19 Intellectual Property
    Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    Arbutus Stock Soars 20% As It Heads To Trial With Moderna In Covid Vaccine Patent Claim
    Via Benzinga
    Topics Intellectual Property
    Exposures COVID-19 Intellectual Property
    Arbutus to Participate in Two Upcoming Investor Conferences
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    Arbutus to Present at Jefferies London Healthcare Conference
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.